Cargando…

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents

Detalles Bibliográficos
Autores principales:	Reis, Ben Y., Barda, Noam, Leshchinsky, Michael, Kepten, Eldad, Hernán, Miguel A., Lipsitch, Marc, Dagan, Noa, Balicer, Ran D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552532/ https://www.ncbi.nlm.nih.gov/pubmed/34670036 http://dx.doi.org/10.1056/NEJMc2114290

Ejemplares similares

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Indirect protection of children from SARS-CoV-2 infection through parental vaccination
por: Hayek, Samah, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
por: Auster, Oren, et al.
Publicado: (2022)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
por: Hayek, Samah, et al.
Publicado: (2022)

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
por: Kustin, Talia, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
por: Katz, Mark A., et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
por: Sheikh, Aziz, et al.
Publicado: (2021)

Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
por: Waxman, Jacob G., et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
por: Dagan, Noa, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population
por: Ben Shachar, Shay, et al.
Publicado: (2021)

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
por: Gray, Glenda, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9qjr3lci6jl2b1u1k4vfg60k18